April 26, 2023 07:54 ET | Source: Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk's Articles of Association 2023 after capital reduction, 26 April 2023
Attachment
Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health
Novo and Hengrui Pharma enter 2.6 billion USD license agreement for obesity and diabetes pill that could potentially be taken only once every week
